Oxford Nanopore Technologies

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

Retrieved on: 
수요일, 4월 24, 2024
Neoplasm, Cancer, Blood, AI, Recurrence, Partnership, Artificial intelligence, Therapy, Acquisition, CSO, Health, Molecular biology, Letter, Oxford Nanopore Technologies, Medical imaging

RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.

Key Points: 
  • RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.
  • Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy.
  • Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies.
  • Additionally, Cyclomics' OmniOmics 4th generation technology enables reliable, fast, and ultra-sensitive early detection of cancer or recurrence thereof using next-generation whole genome sequencing.

Proposed Changes to BenevolentAI’s Board Composition

Retrieved on: 
월요일, 4월 15, 2024
Technology, Research, Finance, Health Technology, Professional Services, Biotechnology, Health, Science, Artificial Intelligence, Annual general meeting, CFO, Cure, Investment, AI, Neo-noir, Partnership, Business, Growth, Corporate development, GI Partners, BAI, Intellectual property, Drug discovery, LifeArc, AIM, Trust, Amphisbaena, Nomination, Therapy, Euronext Amsterdam, Abcam, P74, Research and development, Trustee, Artificial intelligence, Observation, Chairperson, Digital, Recipharm, Partner, Government, Sale, The Carlyle Group, Business development, Accel-KKR, Senior, Acquisition, F2G, Risk, Audit, AGM, Oxford Nanopore Technologies, Management

Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.

Key Points: 
  • Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.
  • Subject to their appointment at the AGM, it is proposed that Mr. Allen acts as Chair and Mr. Mulvany acts as Deputy Chair of the Board.
  • Together with the rest of the Board, they will support Chief Executive Dr. Jeorg Moeller and his team on implementing the Company’s strategy.
  • He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004 and a Board Trustee of LifeArc, a leading UK medical research charity.

Clinical Microbiomics Launches Advanced Long-Read 16S, ITS, 18S, Isolate, and Metagenomics Sequencing Services

Retrieved on: 
화요일, 4월 23, 2024
P24, ITS, Genomics, CCO, Metagenomics, Health, Probiotic, Business development, Nielsen, ONT, Research, Disease, DNA, Acquisition, Oxford Nanopore Technologies, Metabolomics, Prebiotic (nutrition), Algorithm

COPENHAGEN, Denmark, April 23, 2024 /PRNewswire/ -- Clinical Microbiomics, a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services. Tailored to meet the stringent requirements of academic, clinical, and industrial researchers, the expanded offerings deliver unmatched insights into microbial communities, featuring the industry's highest quality scores and read lengths.

Key Points: 
  • COPENHAGEN, Denmark, April 23, 2024 /PRNewswire/ -- Clinical Microbiomics , a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services.
  • Anders Grøn, CEO, states, "Our enhanced long-read sequencing capabilities are redefining the standards in microbial analysis and microbiome research.
  • Dr. Henrik Bjørn Nielsen , Chief Scientific Officer, states, "Our new long-read sequencing services represent a significant advancement in microbiome research.
  • Clinical Microbiomics' long-read sequencing services are globally available, supported by state-of-the-art laboratories in Denmark and the United States.

Oxford Nanopore Technologies and SeqOne Partner to Support Interpretation of Nanopore Sequencing in Clinical Use

Retrieved on: 
월요일, 3월 11, 2024
Health Technology, Technology, Nanotechnology, Pharmaceutical, Oncology, Professional Services, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, WGS, Nephrology, APHP, STR, Single-nucleotide polymorphism, Partnership, CFH, Patient, Chelsea Handler, RUO, HPO, Oxford Nanopore Technologies, Thrombotic microangiopathy, Developed country, Nanopore sequencing, Thrombosis, CNV, Pharmaceutical industry

Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.

Key Points: 
  • Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.
  • It also enables one-click HPO extraction from clinical notes with the DiagAI Notes2HPO large language model.
  • In the future, the collaboration will deliver other variant interpretation applications addressing the needs of cancer predisposition and somatic analysis.
  • “We are excited to collaborate with SeqOne to provide end-to-end solutions for our customers in rare disease and oncology.

SPT Labtech and RevoluGen Demonstrate Fully Automated Bead-Based High Molecular Weight DNA Extraction

Retrieved on: 
수요일, 2월 28, 2024
DNA, SPT, HMW, Risk, Corporate development, Automation, Genomics, N50, Corporation, Laboratory, Communication, Oxford Nanopore Technologies, Workflow, Fine chemical

HADFIELD, United Kingdom, Feb. 28, 2024 (GLOBE NEWSWIRE) -- SPT Labtech, a global leader in the design, development and manufacture of automated instrumentation and consumables for life science applications, and RevoluGen Ltd. (RevoluGen), a UK genomics company, announce the successful automation of RevoluGen’s Fire Monkey™ High Molecular Weight (HMW) DNA extraction chemistry in a bead-based format using SPT Labtech’s firefly® automated liquid handling platform.

Key Points: 
  • HADFIELD, United Kingdom, Feb. 28, 2024 (GLOBE NEWSWIRE) -- SPT Labtech, a global leader in the design, development and manufacture of automated instrumentation and consumables for life science applications, and RevoluGen Ltd. (RevoluGen), a UK genomics company, announce the successful automation of RevoluGen’s Fire Monkey™ High Molecular Weight (HMW) DNA extraction chemistry in a bead-based format using SPT Labtech’s firefly® automated liquid handling platform.
  • The automated protocol enables the processing of up to 96 samples in parallel to prepare HMW DNA suitable for library preparation for long-read sequencing in under two hours.
  • To achieve this, RevoluGen has applied its Fire Monkey High Molecular Weight DNA extraction chemistry to develop a magnetic bead-based DNA extraction method that is compatible with the liquid handling volumes and broad capabilities of SPT Labtech’s firefly automated liquid handling instrument.
  • “This combination of Fire Monkey reagents and firefly’s automation capabilities represents an excellent fit for long-read sequencing users seeking an automated solution for High Molecular Weight DNA extraction.

Oxford Nanopore launches PromethION 2 Integrated into open early access

Retrieved on: 
목요일, 3월 7, 2024
Health, Genetics, Other Science, General Health, Research, Science, Love, A-DNA, Oxford Nanopore Technologies, NetBurst (microarchitecture), P2i, Animal, Plant, RNA, Early access, Nanopore sequencing, DNA, Video game

Oxford Nanopore Technologies today announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete its PromethION product range.

Key Points: 
  • Oxford Nanopore Technologies today announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete its PromethION product range.
  • Each flow cell will be capable of delivering the lowest price per Gb for Oxford Nanopore sequencing, providing a rapid and convenient solution for achieving the coverage required for sequencing larger genomes.
  • Since being rolled out in beta access in November 2023, several institutions have put the device to the test with remarkable success.
  • “With the launch of the P2i, Oxford Nanopore is heralding a new era of sequencing technology, offering a fully integrated, plug-and-play device that opens up unparalleled possibilities in both research and applied markets.

Droplet-based Whole Genome Amplification: Successfully Sequencing Minute Amounts of Mycobacterium Tuberculosis DNA, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
수요일, 2월 28, 2024
Whole genome sequencing, ONT, Tree (graph theory), Drug resistance, University of Antwerp, TB, WGS, Research, University, Health, Genome, MAGMA, Nanopore sequencing, Mycobacterium tuberculosis, Tuberculosis, DNA, Oxford Nanopore Technologies, Vaccine

TORONTO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Whole genome sequencing (WGS) is crucial for tuberculosis (TB) surveillance, but its implementation in patient care is hindered by the limited amount of Mycobacterium tuberculosis (Mtb) in clinical specimens and the slow growth of Mtb.

Key Points: 
  • In this free webinar, delve into the significance of whole genome sequencing (WGS) in advancing tuberculosis (TB) surveillance.
  • Attendees will learn how droplet-based multiple displacement amplification (dMDA) coupled with WGS helped successfully sequence minute amounts of Mtb DNA.
  • The control and 5 pg input dMDA samples underwent nanopore sequencing and were analysed using nanorate sequencing (Nanoseq) and TB-profiler.
  • Register for this webinar today to gain insights into how dMDA amplification coupled with whole genome sequencing helped successfully sequence minute amounts of Mtb DNA.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
목요일, 2월 15, 2024
Closing, Neoplasm, Algorithm, Recurrence, Epigenomics, Oxford Nanopore Technologies, Doctor of Philosophy, LOS, LON, AI, MD, Blood, LOI, Partnership, Cancer, Lung cancer, Liquid biopsy, TP53, Cell, Metabolomics, Diagnosis, Triple-negative breast cancer, Physical examination, Carcinoma, Patient, Proteomics, Genomics, Deep learning, HNC, Nvidia, DNA, IVD, NVIDIA, Medical imaging

LOS ANGELES and AMSTERDAM, Feb. 15, 2024 (GLOBE NEWSWIRE) -- GEDiCube (moving forward RenovaroCube), a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • The focus is on early cancer- and early recurrence detection, prediction of response to therapy, and personalized treatment, all via liquid biopsy tests.

Wasatch Biolabs Launches Proprietary Targeted DNA Methylation Sequencing Service for Researchers and Healthcare Providers

Retrieved on: 
화요일, 2월 13, 2024
Methylation, Nanopore, A-DNA, Oxford Nanopore Technologies, WBL, Cancer, Drug development, Entrepreneurship, RNA, Gene expression, Nanopore sequencing, Disease, PCR, DNA methylation, Research, DNA, AMR, Fine chemical

HEBER CITY, Utah, Feb. 13, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL) , a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies' laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers.

Key Points: 
  • HEBER CITY, Utah, Feb. 13, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL) , a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies' laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers.
  • The DNA methylation service is being released among WBL's first wave of Oxford Nanopore-based sequencing services, and is the company's first big step toward making Oxford Nanopore sequencing and the power of epigenetics more accessible to researchers and healthcare providers.
  • Bisulfite sequencing, which involves chemical treatment of DNA with sodium bisulfite and PCR amplification, remains the de facto standard for DNA methylation analysis.
  • In addition to its proprietary DNA methylation sequencing service, WBL also offers other Oxford Nanopore assay-based sequencing services, including whole genome, cDNA, and RNA sequencing, among others, to researchers and clinical service providers.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
화요일, 2월 13, 2024
Closing, Neoplasm, Algorithm, Recurrence, Epigenomics, Oxford Nanopore Technologies, Doctor of Philosophy, LOS, LON, MD, Blood, LOI, Partnership, Cancer, Lung cancer, Liquid biopsy, TP53, Cell, Metabolomics, Diagnosis, Triple-negative breast cancer, Physical examination, Carcinoma, Patient, Proteomics, Genomics, Deep learning, HNC, Nvidia, DNA, IVD, NVIDIA, Medical imaging

LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • I consider that to be a significant step towards bringing early detection of cancer to its inflection point.”